Evaluation of Drug Treatment of Bronchopneumonia at the Pediatric Clinic in Sarajevo.
BACKGROUND
Bronchopneumonia is the most common clinical manifestation of pneumonia in pediatric population and leading infectious cause of mortality in children under 5 years. Evaluation of treatment involves diagnostic procedures, assessment of disease severity and treatment for disease with an emphasis on vulnerability of the population.


OBJECTIVE
To determine the most commonly used antibiotics at the Pediatric Clinic in Sarajevo and concomitant therapy in the treatment of bronchopneumonia.


METHODS
The study was retrospective and included a total of 104 patients, hospitalized in pulmonary department of the Pediatric Clinic in the period from July to December 2014. The treatment of bronchopneumonia at the Pediatric Clinic was empirical and it conformed to the guidelines and recommendations of British Thoracic Society.


CONCLUSIONS
First and third generation of cephalosporins and penicillin antibiotics were the most widely used antimicrobials, with parenteral route of administration and average duration of treatment of 4.3 days. Concomitant therapy included antipyretics, corticosteroids, leukotriene antagonists, agonists of β2 adrenergic receptor. In addition to pharmacotherapy, hospitalized patients were subjected to a diet with controlled intake of sodium, which included probiotic-rich foods and adequate hydration. Recommendations for further antimicrobial treatment include oral administration of first-generation cephalosporins and penicillin antibiotics.


CONCLUSIONS
Results of the drug treatment of bronchopneumonia at the Pediatric Clinic of the University Clinical Center of Sarajevo are comparable to the guidelines of the British Thoracic Society. It is necessary to establish a system for rational use of antimicrobial agents in order to reduce bacterial resistance.
Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Bosnia and Herzegovina.
Svjetlana Loga
SL
Zec
Faculty of Medicine, University of Sarajevo, Bosnia and Herzegovina.
Kenan
K
Selmanovic
Department of Neurology, Clinical Center University of Sarajevo, Bosnia and Herzegovina.
Natasa Loga
NL
Andrijic
Faculty of Medicine, University of Sarajevo, Bosnia and Herzegovina.
Azra
A
Kadic
Institute of Clinical Immunology, Clinical Center University of Sarajevo, Bosnia and Herzegovina.
Lamija
L
Zecevic
Department of Pharmacology, Faculty of Health Sciences, University of Zenica, Zenica.
Lejla
L
Zunic
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D017522:Bosnia and Herzegovina / Q000453:epidemiology; D001996:Bronchopneumonia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002673:Child, Hospitalized; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006776:Hospitals, Pediatric; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents
bronchopneumonia; clinical features; diagnostic procedures; drug therapy; pediatric population